Migraine is one of the most prevalent neurological disorders among all age groups including the elderly, but the incidence and prevalence of migraine tend to decrease with age. The clinical phenotype of migraine also appears to be different in the elderly patient group in comparison to the younger patient group, with elderly migraine appearing to be more often bilateral and associated with what has become known as “late-life migraine accompaniments. Furthermore, difficulty in the differentiation of migraine from vascular insults such as transient ischemic attacks and amyloid angiopathy and other multiple comorbidities, polypharmacy and age-related changes in pharmacodynamics and pharmacokinetics makes treatments for this cohort challenging but necessary, especially given the worldwide increase in life expectancy, and likelihood of migraine continuing to be a major personal and public health problem.

Keywords:
Calcitonin gene-related peptide, Migraine, Prevalence, Elderly
1.
Stark RJ, Ravishankar K, Siow HC, Lee KS, Pepperle R, Wang SJ: Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review. Cephalalgia 2013; 33: 266–283.
2.
Stark RJ, Valenti L, Miller GC: Management of migraine in Australian general practice. Med J Aust 2007; 187: 142–146.
3.
Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, et al: Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. Mayo Clin Proc 2016;pii:S0025-6196(16)00126-9.
4.
Dodick DW, Loder EW, Manack Adams A, Buse DC, Fanning KM, Reed ML, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache 2016; 56: 821–834.
5.
Feigin VL, Abajobir AA, Abate KH, Abd-Allah F, Abdulle AM, Abera SF, et al. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017; 16: 877–897.
6.
Goadsby PJ: Migraine: diagnosis and management. Intern Med J 2003; 33: 436–442.
7.
Haan J, Hollander J, Ferrari MD: Migraine in the elderly: a review. Cephalalgia 2007; 27: 97–106.
8.
Stewart WF, Lipton RB, Celentano DD, Reed ML: Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64–69.
9.
Burch R, Rizzoli P, Loder E: The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache 2018; 58: 496–505.
10.
Burch RC, Loder S, Loder E, Smitherman TA: The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 2015; 55: 21–34.
11.
de Rijk P, Resseguier N, Donnet A: Headache characteristics and clinical features of elderly migraine patients. Headache 2018; 58: 525–533.
12.
Lisotto C, Mainardi F, Maggioni F, Zanchin G: Headache in Sturge-Weber syndrome: a case report and review of the literature. Cephalalgia 2004; 24: 1001–1004.
13.
Lisotto C, Mainardi F, Maggioni F, Zanchin G: Episodic hypnic headache? Cephalalgia 2004; 24: 681–685.
14.
Martins KM, Bordini CA, Bigal ME, Speciali JG: Migraine in the elderly: a comparison with migraine in young adults. Headache 2006; 46: 312–316.
15.
Prencipe M, Casini AR, Ferretti C, Santini M, Pezzella F, Scaldaferri N, et al: Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry 2001; 70: 377–381.
16.
Starling AJ: Diagnosis and management of headache in older adults. Mayo Clin Proc 2018; 93: 252–262.
17.
Wober-Bingol C, Wober C, Karwautz A, Auterith A, Serim M, Zebenholzer K, et al: Clinical features of migraine: a cross-sectional study in patients aged three to sixty-nine. Cephalalgia 2004; 24: 12–17.
18.
Kelman L: Migraine changes with age: IMPACT on migraine classification. Headache 2006; 46: 1161–1171.
19.
Landy S: Migraine throughout the life cycle: treatment through the ages. Neurology 2004; 62(5 suppl 2):S2–S8.
20.
Landy SH, Lobo BL: Migraine treatment throughout the lifecycle. Expert Rev Neurother 2005; 5: 343–353.
21.
Linn J, Schwarz F, Reinisch V, Straube A: Ophthalmoplegic migraine with paresis of the sixth nerve: a neurovascular compression syndrome? Cephalalgia 2008; 28: 667–670.
22.
Camarda R, Monastero R: Prevalence of primary headaches in Italian elderly: preliminary data from the Zabut Aging Project. Neurol Sci 2003; 24(suppl 2):S122–S124.
23.
Sharma TL: Common primary and secondary causes of headache in the elderly. Headache 2018; 58: 479–484.
24.
Feleppa M, Fucci S, Bigal ME: Primary headaches in an elderly population seeking medical care for cognitive decline. Headache 2017; 57: 209–216.
25.
Reinisch VM, Schankin CJ, Felbinger J, Sostak P, Straube A. [Headache in the elderly]. Schmerz 2008; 22(suppl 1): 22–30.
26.
Jelicic M, van Boxtel MP, Houx PJ, Jolles J: Does migraine headache affect cognitive function in the elderly? Report from the Maastricht Aging Study (MAAS). Headache 2000; 40: 715–719.
27.
Fisher CM: Late-life migraine accompaniments–further experience. Stroke 1986; 17: 1033–1042.
28.
Fisher CM: Late-life migraine accompaniments as a cause of unexplained transient ischemic attacks. Can J Neurol Sci 1980; 7: 9–17.
29.
Manusov EG: Late-life migraine accompaniments: a case presentation and literature review. J Fam Pract 1987; 24: 591–594.
30.
Vongvaivanich K, Lertakyamanee P, Silberstein SD, Dodick DW: Late-life migraine accompaniments: a narrative review. Cephalalgia 2015; 35: 894–911.
31.
Sequeira D, Martin-Gill C, Kesinger MR, Thompson LR, Jovin TG, Massaro LM, et al: Characterizing strokes and stroke mimics transported by helicopter emergency medical services. Prehospital Emergency Care 2016; 20: 723–728.
32.
Goyal N, Tsivgoulis G, Male S, Metter EJ, Iftikhar S, Kerro A, et al: FABS: an intuitive tool for screening of stroke mimics in the emergency department. Stroke 2016; 47: 2216–2220.
33.
Vroomen PC, Buddingh MK, Luijckx GJ, De Keyser J: The incidence of stroke mimics among stroke department admissions in relation to age group. J Stroke Cerebrovasc Dis 2008; 17: 418–422.
34.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1–211.
35.
Baranzini F, Poloni N, Diurni M, Ceccon F, Colombo D, Colli C, et al: [Polypharmacy and psychotropic drugs as risk factors for falls in long-term care setting for elderly patients in Lombardy]. Recenti Prog Med 2009; 100: 9–16.
36.
Salwe KJ, Kalyansundaram D, Bahurupi Y: A study on polypharmacy and potential drug-drug interactions among elderly patients admitted in department of medicine of a tertiary care hospital in Puducherry. J Clin Diagn Res 2016; 10:FC06–FC10.
37.
McLean AJ, Le Couteur DG: Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163–184.
38.
Kroll LS, Sjodahl Hammarlund C, Gard G, Jensen RH, Bendtsen L: Has aerobic exercise effect on pain perception in persons with migraine and coexisting tension-type headache and neck pain? A randomized, controlled, clinical trial. Eur J Pain 2018, Epub ahead of print.
39.
Birru EM, Abay Z, Abdelwuhab M, Basazn A, Sirak B, Teni FS: Management of headache and associated factors among undergraduate medicine and health science students of University of Gondar, North West Ethiopia. J Headache Pain 2016; 17: 56.
40.
Suzuki K, Miyamoto M, Miyamoto T, Inoue Y, Matsui K, Nishida S, et al: The prevalence and characteristics of primary headache and dream-enacting behaviour in japanese patients with narcolepsy or idiopathic hypersomnia: a multi-centre cross-sectional study. PLoS One 2015; 10:e0139229.
41.
Dodick DW: Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine). Cephalalgia 2009; 29(suppl 3): 7–14.
42.
Baron EP, Tepper SJ, Mays M, Cherian N: Acute treatment of basilar-type migraine with greater occipital nerve blockade. Headache 2010; 50: 1057–1059.
43.
Tepper SJ, Rezai A, Narouze S, Steiner C, Mohajer P, Ansarinia M: Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache 2009; 49: 983–989.
44.
Tepper SJ, Spears RC: Acute treatment of migraine. Neurol Clin 2009; 27: 417–427.
45.
Da Silva AN, Tepper SJ: Acute treatment of migraines. CNS Drugs 2012; 26: 823–839.
46.
Katic BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME: Adherence to acute migraine medication: what does it mean, why does it matter? Headache 2010; 50: 117–129.
47.
Tepper DE: Non-steroidal anti-inflammatories for the acute treatment of migraine. Headache 2013; 53: 225–226.
48.
Knowles S, Oh P, Gomes T; Ontario Drug Policy Research Network: Triptans for acute migraine: drug class review to help inform policy decisions. Headache 2015; 55(suppl 4): 191–198.
49.
Rapoport AM, Tepper SJ, Sheftell FD, Kung E, Bigal ME: Which triptan for which patient? Neurol Sci 2006; 27(suppl 2):S123–S129.
50.
Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB: Transformed migraine and medication overuse in a tertiary headache centre–clinical characteristics and treatment outcomes. Cephalalgia 2004; 24: 483–490.
51.
Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB: Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015; 35: 478–488.
52.
Diener HC, Limmroth V: Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001; 10: 1831–1845.
53.
Reinke T: Aimovig for migraine prevention: the new kid may have trouble fitting in. Manag Care 2018; 27: 10–11.
54.
Raffaelli B, Reuter U: The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics 2018; 15: 324–335.
55.
Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM: Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache 2004; 44: 794–800.
56.
Paemeleire K, MaassenVanDenBrink A: Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Curr Opin Neurol 2018; 31: 274–280.
57.
Israel H, Neeb L, Reuter U: CGRP monoclonal antibodies for the preventative treatment of migraine. Curr Pain Headache Rep 2018; 22: 38.
58.
Maizels M, Blumenfeld A, Burchette R: A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004; 44: 885–890.
59.
Zhu Y, Liu Y, Zhao J, Han Q, Liu L, Shen X: The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol Sci 2018, Epub ahead of print.
60.
Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, et al: Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache 2017; 57: 1375–1384.
61.
Ohlsson L, Kronvall E, Stratton J, Edvinsson L: Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. J Headache Pain 2018; 19: 66.
62.
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al: Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017; 377: 2113–2122.
63.
Edvinsson L, Haanes KA, Warfvinge K, Krause DN: CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol 2018; 14: 338–350.
64.
Jin Y, Smith C, Monteith D, Brown R, Camporeale A, McNearney TA, et al: CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial. Osteoarthritis Cartilage 2018;pii:S1063-4584(18)31459-6.
65.
Edvinsson L: The CGRP pathway in migraine as a viable target for therapies. Headache 2018; 58(suppl 1): 33–47.
66.
Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, et al: Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol 2018; 75: 187–193.
67.
Loder E, Biondi D: General principles of migraine management: the changing role of prevention. Headache 2005; 45(suppl 1):S33–S47.
68.
Hagen K, Asberg AN, Uhlig BL, Tronvik E, Brenner E, Stjern M, et al: The epidemiology of headache disorders: a face-to-face interview of participants in HUNT4. J Headache Pain 2018; 19: 25.
69.
Zhang Y, Shi Z, Hock D, Yue W, Liu S, Zhang Y, et al: Prevalence of primary headache disorders in a population aged 60 years and older in a rural area of Northern China. J Headache Pain 2016; 17: 83.
70.
Ruiz M, Pedraza MI, de la Cruz C, Baron J, Munoz I, Rodriguez C, et al: Headache in the elderly: characteristics in a series of 262 patients. Neurologia (Barcelona, Spain) 2014; 29: 321–326.
71.
Schwaiger J, Kiechl S, Seppi K, Sawires M, Stockner H, Erlacher T, et al: Prevalence of primary headaches and cranial neuralgias in men and women aged 55–94 years (Bruneck Study). Cephalalgia 2009; 29: 179–187.
72.
Tai ML, Jivanadham JS, Tan CT, Sharma VK: Primary headache in the elderly in South-East Asia. J Headache Pain 2012; 13: 291–297.
73.
Kurth T, Mohamed S, Maillard P, Zhu YC, Chabriat H, Mazoyer B, et al: Headache, -migraine, and structural brain lesions and -function: population based Epidemiology of Vascular Ageing-MRI study. BMJ 2011; 342: c7357.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.